The average astrocytoma treatment cost in China typically includes surgical options like craniotomy, which runs from $22,500 to $44,000. For targeted non-invasive care, stereotaxic radiosurgery ranges from $8,500 to $15,800. Total expenses depend on the tumor grade, hospital classification, and required chemotherapy cycles. Patients can achieve 65% to 85% savings compared to the US. Top medical destinations include Beijing, Shanghai, and Guangzhou.
Typical Astrocytoma Treatment Costs in China
Bookimed Expert Insight: For complex neuro-oncology cases, tertiary hospitals like Xiamen Humanity Hospital offer advanced infrastructure including 47 specialized departments. Patients seeking cutting-edge protocols may benefit from clinics accredited for Phase I–IV drug trials. For high-precision radiotherapy, experts like Dr. Liu Shi Xin provide specialized experience in VMAT and SBRT technologies. These high-volume centers manage over 1,000,000 patients annually, balancing innovative clinical trials with established surgical care.
| China | Türkei | Österreich | |
| Strahlentherapie bei Darmkrebs | von $11,500 | von $7,000 | von $12,000 |
| Stereotaktische Radiochirurgie | von $8,500 | von $4,500 | von $17,000 |
| Kraniotomie | von $22,500 | von $5,650 | von $20,000 |
| Chemotherapie bei Brustkrebs | von $14,800 | von $1,200 | von $15,000 |
| Halcyon | - | von $5,400 | - |
Bookimed erhebt keine zusätzlichen Gebühren für Astrozytom-Behandlungspreise. Die Preise stammen aus den offiziellen Preislisten der Kliniken. Sie zahlen direkt in der Klinik für Ihre Behandlung bei Ihrer Ankunft im Land.
Bookimed setzt sich für Ihre Sicherheit ein. Wir arbeiten nur mit medizinischen Einrichtungen zusammen, die hohe internationale Standards bei der Behandlung von Astrozytom einhalten und über die notwendigen Lizenzen verfügen, um internationale Patienten weltweit zu behandeln.
Bookimed bietet kostenlose fachliche Unterstützung. Ein persönlicher medizinischer Koordinator unterstützt Sie vor, während und nach Ihrer Behandlung und hilft Ihnen bei allen Fragen. Sie sind auf Ihrer Astrozytom-Behandlungsreise nie allein.
Professor Shixin Liu, MD, PhD, ist Fachbereichsleiter des Onkologiezentrums. Zuvor war er Präsident des Krebskrankenhauses der Provinz Jilin und Direktor des Forschungsinstituts für Krebsprävention und -therapie. Er ist Professor der zweiten Ebene und Promotionsbetreuer. Er erhielt die Sonderzulage des Staatsrats, die 4. Auszeichnung 'National Famous Doctor (Outstanding Contribution)' sowie den Ehrentitel 'Vorbild ärztlicher Ethik'.
Er ist auf die umfassende Diagnostik und Behandlung bösartiger Tumoren spezialisiert, mit Schwerpunkt auf präziser Strahlentherapie thorakaler und abdomineller Tumoren. Er beherrscht IMRT, VMAT und SBRT bei Lungen-, Speiseröhren-, Brust- und Rektumkarzinomen.
Zu seinen Leitungsfunktionen zählen die stellvertretenden Vorsitzämter bei CMA Radiation Oncology, CACA Radiotherapy und CACA Particle Therapy. Er gehört dem Ständigen Ausschuss der CSCO an und ist stellvertretender Vorsitzender des CSCO-Expertenkomitees für Strahlenonkologie. Zudem ist er stellvertretender Vorsitzender der CPAM Radiation Oncology und Mitglied des Ständigen Ausschusses der CSMEA. Er ist Vorsitzender der Sektion Strahlenonkologie der Jilin Medical Association. Er gehört den Redaktionsbeiräten des Chinese Journal of Radiation Oncology und des Practical Journal of Cancer an.
An astrocytoma is a brain or spinal cord tumor developing from star-shaped cells called astrocytes. The World Health Organization (WHO) classifies these into four grades. Grade 1 and 2 tumors grow slowly. Grade 3 and 4 tumors are aggressive and spread rapidly into tissue.
Bookimed Expert Insight: Chinese oncology centers like Xiamen Humanity Hospital manage over 1,000,000 patients annually. They use advanced techniques like SBRT and Oncothermia for complex cases. Large patient volumes often lead to high proficiency in navigating eloquent brain regions. Confirm if your center offers IMRT or VMAT technology. These systems allow radiation to spare healthy brain tissue more effectively.
Patient Consensus: Patients emphasize that successful surgery means balancing tumor removal with the preservation of speech and movement. Many travelers recommend getting a pathology report that includes molecular markers like IDH status before starting chemo.
Seeking a second opinion on an astrocytoma pathology report is highly recommended before starting treatment. Experts emphasize that brain tumor classification is complex. A specialist review confirms molecular markers like IDH mutations. It ensures you receive the correct grade for personalized care.
Bookimed Expert Insight: High-volume Chinese centers like Xiamen Humanity Hospital serve 1,000,000 patients annually. Large institutions often have accredited labs for phase I-IV drug trials. This scale usually indicates deeper experience with the complex molecular testing needed for astrocytoma. Always verify if a facility has specific clinical trial accreditations for your tumor subtype.
Patient Consensus: Patients note a second review is worth double-checking because glioma diagnosis is technically tricky. They emphasize that modern treatment decisions depend heavily on molecular details rather than just microscopic views.
Beijing Tiantan Hospital and Huashan Hospital are the primary centers for astrocytoma surgery in China. These facilities utilize intraoperative MRI and fluorescence-guided resection for complex gliomas. Leading institutions maintain specialized neuro-oncology multidisciplinary teams and perform thousands of successful brain tumor resections annually.
Bookimed Expert Insight: Xiamen Humanity Hospital stands out as a tertiary center serving 1,000,000 patients yearly with 460 doctors. For astrocytoma patients specifically, the presence of Dr. Liu Shi Xin is a major factor. He holds the National Famous Doctor award and serves as Vice Chairman of the Radiation Oncology Branch. His expertise in precision radiotherapy like IMRT and VMAT is essential for managing high-grade astrocytomas after surgery.
Patient Consensus: Patients emphasize finding surgeons who specifically focus on gliomas rather than general neurosurgery. They note that coordinating pathology and radiation in one location prevents dangerous treatment delays.
Chinese hospitals employ advanced neurosurgical systems like the Remebot and Tianji robotics for high-precision tumor resections. These platforms utilize AI-driven navigation and multispectral tracking to achieve 0.1mm accuracy. Institutions like Xiamen Humanity Hospital provide comprehensive neuro-oncology care within tertiary facilities serving 1,000,000 patients annually.
Bookimed Expert Insight: While many focus on robotics, the true differentiator in Chinese neuro-oncology is the integration of massive patient volumes with domestic innovation. Xiamen Humanity Hospital alone manages 1,000,000 patients every year. This high volume allows surgeons like Dr. Liu Shi Xin to master specialized techniques like VMAT and SBRT for complex tumors much faster than in lower-volume regional centers.
Patient Consensus: Patients emphasize that molecular profiling for IDH mutations and MGMT status is now essential for modern astrocytoma treatment. They note that choosing a surgeon who performs high annual volumes of glioma resections is more critical than the specific robotic brand used.
Chinese neuro-oncology centers offer specialized radiation therapies including proton beam therapy, carbon ion radiotherapy, and boron neutron capture therapy. These facilities use precision technologies like Intensity-Modulated Radiation Therapy and stereotactic radiosurgery to destroy tumor cells while preserving healthy brain tissue and neurocognitive function.
Bookimed Expert Insight: Leadership in Chinese radiation oncology is concentrated in specialists with significant academic influence. Professor Liu Shi Xin at Xiamen Humanity Hospital serves as Vice Chairman of the Particle Therapy Professional Committee. This institutional link suggests that academic tertiary centers in China integrate particle therapy research directly into clinical practice for complex brain tumors.
Patient Consensus: Patients emphasize the need to ask how a radiation plan protects the hippocampus and optic nerves. They note that specialized centers are preferred for younger patients to reduce long-term side effects.
Temozolomide is widely available in China for treating high-grade astrocytoma. The drug has been on the market for over 20 years. Patients can access both imported brand-name Temodar and domestic generics. Chinese oncologists follow the global Stupp protocol standard for malignant gliomas.
Bookimed Expert Insight: While Temozolomide is common, hospital specialization matters for drug access. Centers like Xiamen Humanity Hospital manage 1,000,000 patients annually and possess infrastructure for drug trials. Large-scale tertiary hospitals are more likely to have consistent stock of both imported and domestic versions compared to smaller clinics.
Patient Consensus: Patients suggest asking for the generic name instead of specific brands to ensure availability. They also emphasize confirming if the hospital can dispense the medication directly to simplify the logistics of each cycle.
China integrates Traditional Chinese Medicine (TCM) as a supportive, non-primary therapy for astrocytoma. Medical teams use it alongside surgery, radiation, and chemotherapy. The focus remains on easing treatment side effects. This approach helps boost immune function and patient comfort during recovery phases.
Bookimed Expert Insight: TCM integration is built into the hospital culture at major institutions like Xiamen Humanity Hospital. This center handles 1,000,000 patients annually and performs complex drug trials. Expert oncologists like Dr. Liu Shi Xin work in facilities that combine standard radiation like VMAT with supportive care. This indicates that high-volume Chinese hospitals prioritize a unified, medical-grade approach over separate alternative clinics.
Patient Consensus: Patients note that TCM provides emotional reassurance when prognosis is uncertain. They emphasize using it only as an add-on and never delaying surgery for herbal treatments.